Dr. Mark Sirgo is Chief Executive Officer of Aruna Bio. Dr. Sirgo brings over 35 years of pharmaceutical experience to Aruna Bio from drug development through global product commercialization. Most recently, Dr. Sirgo served as President and CEO of BioDelivery Sciences International (BDSI:Nasdaq), a specialty pharmaceutical company focused in CNS/pain. While leading BDSI, Dr. Sirgo was successful in raising nearly $600 million in capital through partnerships and financings to support the development, FDA approval and commercial launch of three products utilizing the company’s proprietary drug delivery technology.
Dr. Sirgo began his career in clinical development and transitioned in time to marketing at Glaxo, GlaxoWellcome and GlaxoSmithKline including Vice President of International OTC Development and Vice President of New Product Marketing. This included Dr. Sirgo’s responsibility for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome. Dr. Sirgo also served as Senior Vice President of Business Development at Pharmaceutical Product Development (PPDI: Nasdaq).
Along with his role at Aruna Bio, Dr. Sirgo serves on the Board of Directors for a number of pharmaceutical and medical diagnostic companies including BioDelivery Sciences, BioMerica, Inc (BMRX:Nasdaq), 9 Meters Biopharma (Nasdaq: NMTR), Ltd and formerly Salix Pharmaceuticals (SLXP:Nasdaq). He earned a Bachelor of Science in Pharmacy from The Ohio State University and a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Sciences.